Poseida Therapeutics Valuation
| PSTX Stock | USD 9.33 0.05 0.53% |
At this time, the company appears to be undervalued. Poseida Therapeutics holds a recent Real Value of $9.89 per share. The prevailing price of the company is $9.33. Our model determines the value of Poseida Therapeutics from analyzing the company fundamentals such as Return On Equity of -0.58, operating margin of 0.28 %, and Shares Outstanding of 97.47 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Poseida Therapeutics' valuation include:
Price Book 10.4829 | Enterprise Value 766.1 M | Enterprise Value Ebitda (1.24) | Price Sales 6.0279 | Enterprise Value Revenue 5.0783 |
Undervalued
Today
Please note that Poseida Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of Poseida Therapeutics is based on 3 months time horizon. Increasing Poseida Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Poseida Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Poseida Stock. However, Poseida Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 9.33 | Real 9.89 | Target 12.25 | Hype 9.03 |
The intrinsic value of Poseida Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Poseida Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Poseida Therapeutics helps investors to forecast how Poseida stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Poseida Therapeutics more accurately as focusing exclusively on Poseida Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Poseida Therapeutics' intrinsic value based on its ongoing forecasts of Poseida Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Poseida Therapeutics' closest peers.
Poseida Therapeutics Cash |
|
Poseida Valuation Trend
Analysing the historical paterns of Poseida Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Poseida Therapeutics over time and is usually enough for investors to make rational market timing decisions.
Poseida Therapeutics Total Value Analysis
Poseida Therapeutics is at this time anticipated to have valuation of 766.1 M with market capitalization of 909.36 M, debt of 85.42 M, and cash on hands of 142.56 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Poseida Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
766.1 M | 909.36 M | 85.42 M | 142.56 M |
Poseida Therapeutics Investor Information
About 28.0% of the company outstanding shares are owned by corporate insiders. The company has Price/Earnings (P/E) ratio of 214.0. Poseida Therapeutics recorded a loss per share of 0.63. The entity last dividend was issued on the June 23, 1992. The firm had 3:1 split on the April 5, 2005. Based on the key indicators related to Poseida Therapeutics' liquidity, profitability, solvency, and operating efficiency, Poseida Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Poseida Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Poseida Therapeutics has an asset utilization ratio of 23.62 percent. This suggests that the Company is making $0.24 for each dollar of assets. An increasing asset utilization means that Poseida Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Poseida Therapeutics Ownership Allocation
Poseida Therapeutics owns a total of 97.47 Million outstanding shares. Over half of Poseida Therapeutics' outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Poseida Therapeutics Profitability Analysis
The company reported the previous year's revenue of 64.7 M. Net Loss for the year was (123.43 M) with loss before overhead, payroll, taxes, and interest of (22.41 M).About Poseida Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Poseida Therapeutics. We calculate exposure to Poseida Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Poseida Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -92.1 M | -87.5 M | |
| Pretax Profit Margin | (1.91) | (2.00) | |
| Operating Profit Margin | (2.00) | (2.10) | |
| Net Loss | (1.91) | (1.81) | |
| Gross Profit Margin | (1.42) | (1.49) |
Poseida Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 90.2 M |
Poseida Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Poseida Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Poseida we look at many different elements of the entity such as Poseida's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Poseida Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Poseida Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Poseida Therapeutics' worth.Additional Tools for Poseida Stock Analysis
When running Poseida Therapeutics' price analysis, check to measure Poseida Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Poseida Therapeutics is operating at the current time. Most of Poseida Therapeutics' value examination focuses on studying past and present price action to predict the probability of Poseida Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Poseida Therapeutics' price. Additionally, you may evaluate how the addition of Poseida Therapeutics to your portfolios can decrease your overall portfolio volatility.